ArticleInternational journal of women's health2025
Predictive Value of the KELIM Index for Progression-Free Survival in Ovarian Cancer Under Current Treatment Modalities.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Single-cell RNA sequencing in ovarian cancer: decoding the tumor microenvironment for personalized therapy.Journal of ovarian research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The KELIM index, a dynamic biomarker derived from CA125 kinetics, has shown prognostic value in ovarian cancer. However, its predictive role under contemporary treatment paradigms incorporating bevacizumab and PARP inhibitors remains underexplored. Objective: To evaluate the predictive value of the KELIM index for progression-free survival (PFS) in ovarian cancer patients treated with current therapeutic modalities. Methods: A total of 52 patients with ovarian cancer who underwent surgical treatment in the Affiliated Hospital of Jiaxing University from January 1, 2020 to September 30, 2023 were retrospectively analyzed. Clinicopathological data, treatment details (including bevacizumab/PARPi use), and serial CA125 values were collected. The KELIM index was calculated using the online biomarker kinetics tool (https://www.biomarker-kinetics.org/CA125). Cox regression and Kaplan-Meier analyses assessed prognostic factors. Results: The mean age of the 52 patients was 55.17±13.57 years, and the mean body mass index (BMI) was 22.95±3.62kg/m Conclusion: The KELIM index is expected to be another high quality index for predicting OC under the current treatment model, potentially guiding personalized treatment intensification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.